Abstract :
Natural Medicines with anti-inflammatory and anti-oxidant potentials act as adjuvant therapy to increase the effectiveness of standard COVID-19 treatment. The combination of Channa striata, Curcuma xanthorriza, and Moringa oleifera (Onoiwa Mx) administration can complement the treatment of COVID-19 as adjuvant therapy, especially for patients with mild and moderate pneumonia. Therefore, this study aims to assess the combined administration of Channa striata, Curcuma xanthoria, and Moringa Oliefera extracts as adjuvant therapy in standard COVID-19 treatment. The benefits and efficacy to improve the C reactive protein value, length of stay, and better scoring of the shortness scale were provided, and clinical observation was conducted with a prospective cohort study design. Furthermore, the subjects were patients with probable/positive PCR confirmation with moderate COVID-19 pneumonia after fulfilling the inclusion criteria. A total of 48 subjects were obtained and divided into control and treatment groups of 24 patients each. Three variables were analyzed bivariately, namely the LOS, MMRC, and CRP. The results showed that males (62.5%) had the most characteristic of the sample characteristics with an average age of 50.-54 years old, accompanied by symptoms of cough (91.7%), fever (77.1%), and shortness of breath ( 75%). Furthermore, the most common comorbid disease of the two groups was hypertension (47.9%). In conclusion, each fever symptom in the treatment group had a median of 3, which means, 50% recovered after experiencing fever symptoms for 3 days. Meanwhile, the control group had a median of 4, which means, 50% recovered after experiencing fever symptoms for 4 days. Shortness of breath and cough each had a median of 4, which means 50% recovered after 4 days of symptoms. Therefore, the improvement in fever is consistent with that of CRP value, which increases the lymphocyte in the treatment group
